Darya-Varia Laboratoria Tbk PT
IDX:DVLA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 390
1 810
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Darya-Varia Laboratoria Tbk PT
Darya-Varia Laboratoria Tbk PT
Total Liabilities
Darya-Varia Laboratoria Tbk PT
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Total Liabilities
Rp774.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Total Liabilities
Rp3.7T
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Total Liabilities
Rp6.8T
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Total Liabilities
Rp2.3T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Total Liabilities
Rp4.7T
|
CAGR 3-Years
119%
|
CAGR 5-Years
133%
|
CAGR 10-Years
51%
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Total Liabilities
Rp11.5T
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
27%
|
|
Darya-Varia Laboratoria Tbk PT
Glance View
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trade of pharmaceutical products and cosmetics. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,274 full-time employees. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The firm provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The firm also provides Imunped as supplement for kids with Zinc and vitamin C for children.
See Also
What is Darya-Varia Laboratoria Tbk PT's Total Liabilities?
Total Liabilities
774.1B
IDR
Based on the financial report for Sep 30, 2024, Darya-Varia Laboratoria Tbk PT's Total Liabilities amounts to 774.1B IDR.
What is Darya-Varia Laboratoria Tbk PT's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
10%
Over the last year, the Total Liabilities growth was 30%. The average annual Total Liabilities growth rates for Darya-Varia Laboratoria Tbk PT have been 4% over the past three years , 7% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
